IMI 2 is a research-funding initiative, funded by the European Federation of Pharmaceutical Industries and Associations (EFPIA) and the European Commission. It will build upon the success of the Innovative Medicines Initiative (IMI).

The European Commission has officially launched its proposals for IMI 2 with a total budget of €3.45 billion. IMI 2 will benefit from an in-kind contribution from industry of up to €1.725 billion. Whilst €1.5 billion will come from EFPIA companies the remaining €225 million could come from other large companies who wish to contribute to projects but who are not EFPIA members. The European Commission will match-fund industry contributions with up to a maximum of €1.725 billion from Horizon 2020. IMI 2 will help develop the next generation of cost-efficient vaccines, medicines and treatments. It is expected to start in January 2014 and last till 2024.

More information can be found on the IMI website.

Sources: IMI, Euresearch